


CLAIMS

What is claimed is:

1. A method for the solid phase synthesis of oxazolidinones, comprising the steps of:
 - a) attaching an olefin to a solid support;
 - b) oxidizing the olefin to provide an epoxide functionality;
 - c) opening the epoxide with an amine to form an amino alcohol; and
 - d) cyclizing the amino alcohol using a phosgene equivalent.
2. The method according to claim 1, where the olefin is an allylic amine or allylamine.
3. The method according to claim 1, where the amine is an amino acid, or an aromatic amine.
4. A method for the synthesis of oxazolidinone combinatorial libraries, comprising the steps of:
 - a) attaching an olefin group to an array of solid supports;
 - b) oxidizing the individual olefin groups to provide an array of solid support bound epoxides; and
 - c) opening the epoxide with an amine to form an amino alcohol; and
 - d) cyclizing the amino alcohol using a phosgene equivalent.
5. The method according to claim 4, where the olefin is an allylic amine, or allylamine.
6. The method according to claim 4, where the amine units are amino acids or aromatic amines.
7. An oxazolidinone combinatorial library, where the oxazolidinones comprising the library are of the following structure:




where R_1 is selected from the group consisting of alkyl, heteroalkyl, aryl and heteroaryl, R_2 is selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl, R_3 is selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl, R_{11} is selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl, and R_{12} is selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl.

8. The combinatorial library according to claim 7, where R_3 is selected from the group consisting of aryl and heteroaryl, and further where the aryl and heteroaryl groups are the aryl and heteroaryl groups attached to the amines of Table 2 and Figures 29, 30, and 31.

9. The combinatorial library according to claim 7, where R_3 is a heteroaryl group selected from the group consisting of a pyridyl group, a thienylphenyl group, an oxazolyl group, a pyrrolyl group, and a morpholinofluorophenyl group.


10. An antimicrobial compound where the compound is of the structure:



where m is 0, 1, 2 or 3, and where R_{22} , R_{23} and R_{24} are independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl.


11. The antimicrobial compound according to claim 10, where m is 0, and where R_{22} and R_{23} are hydrogen, and where R_{24} is an aryl group.

12. The antimicrobial compound according to claim 11, where the compound is of the structure:



where R_{35} , R_{36} and R_{37} are independently selected from the group consisting of hydrogen, electron withdrawing group, alkyl, heteroalkyl, aryl and heteroaryl.


13. An antimicrobial compound, where the compound has the following structure:



where R_3 is selected from the group consisting of aryl and heteroaryl, and where R_{20} is selected from the group consisting of structures A, B, C, I, J and K




A




B




C



I




J



K

wherein m is 0, 1, 2 or 3, and where n is 0, 1, 2 or 3, and wherein R₂₁ is selected from the group consisting of alkyl, heteroalkyl, aryl and heteroaryl, and where R₂₂, R₂₃ and R₂₄ are independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl, and where R₂₅ is selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and heteroaryl, and where R₃₀ is selected from the group consisting of alkyl, heteroalkyl, aryl and heteroaryl.

14. A compound of formula 2c:



2c

wherein:

R₆ is acyl or sulfonyl;

R₇ is aryl or heteroaryl;

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $NRC(=O)$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$, wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl; and

5 R_9 is hydrogen, OH, alkyl, aryl, heteroalkyl, or heteroaryl.

15. The compound of claim 14 wherein:

R_6 is $C(=O)R$, wherein R is H, alkyl, or aryl;


R_7 is aryl;

10 R_8 is $NH(C=O)$ or $NR'(C=O)$, where R' is H, alkyl, or aryl; and

R_9 is hydrogen, pyridinyl, thiazolyl, benzothiazolyl, isothiazolyl, quinolinyl, 1,3,4-triazolyl, or 1,3,4-thiadiazolyl.

16. A compound of the structure 1b:

15



20 wherein R_2 , R_3 , R_4 and R_5 are, independently, hydrogen alkyl, heteroalkyl, heteroaryl or an electron withdrawing group; R_6 is acyl or sulfonyl; and, R_1 is one of the following functional groups: $C(O)NR_7R_8$, wherein R_7 and R_8 are, independently, hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; $C(O)OR_9$, wherein R_9 is hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; $C(O)R_{10}$, wherein R_{10} is hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; SR_{11} , wherein R_{11} is hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; $S(O)_2R_{11}$, wherein R_{11} is hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; $S(O)R_{11}$, wherein R_{11} is hydrogen, alkyl, heteroalkyl, aryl or heteroaryl; $NR_{12}R_{13}$, wherein R_{12} and R_{13} are, independently, hydrogen, acyl, sulfonyl, alkyl, heteroalkyl, aryl or heteroaryl; 2-oxazolyl,

25

wherein R_{14} is at the 4-position and R_{15} is at the 5-position of the oxazolyl, and wherein R_{14} and R_{15} are, independently, hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or an electron withdrawing group; 2-aminothiazolyl, wherein R_{16} is at the 4-position and R_{17} is at the 5-position of the thiazole, and wherein R_{16} and R_{17} ,
 5 are, independently, hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or an electron withdrawing group; and, $CH_2NR_{18}R_{19}$, wherein R_{18} and R_{19} are, independently, hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, acyl or sulfonyl.

17. A combinatorial library of compounds according to claim 16.

18. A compound of claim 16, wherein R_1 is $C(O)NR_7R_8$, $C(O)OR_9$,
 10 $C(O)R_{10}$, SR_{11} , $S(O)_2R_{11}$, $S(O)R_{11}$ or $NR_{12}R_{13}$.

19. A compound according to claim 16, wherein R_1 is $C(O)NR_7R_8$.

20. A compound according to claim 16, wherein R_1 is $C(O)OR_9$.

21. A compound according to claim 16, wherein R_1 is $C(O)R_{10}$.

22. A compound according to claim 16, wherein R_1 is SR_{11} .

23. A compound according to claim 16, wherein R_1 is $NR_x(C=O)R_y$,
 15 wherein R_x and R_y are independently hydrogen, alkyl, heteroalkyl, aryl, or heteroaryl.

24. A compound according to claim 16, wherein R_1 is $NR_x(SO_2)R_y$,
 20 wherein R_x and R_y are independently hydrogen, alkyl, heteroalkyl, aryl, or heteroaryl with the proviso that R_y is not H.

25. A compound according to claim 16, wherein R_1 is $NR_{12}R_{13}$.

26. A compound according to claim 16, wherein R_1 is 2-oxazolyl,
 wherein R_{14} is at the 4-position and R_{15} is at the 5-position of the oxazole group.

27. A compound according to claim 16, wherein R_1 is 2-
 25 aminothiazolyl, wherein R_{16} is at the 4-position and R_{17} is at the 5-position of the aminothiazolyl group.

28. A compound according to claim 16, wherein R_1 is $CH_2NR_{18}R_{19}$.

29. A compound according to claim 18, wherein R_3 , R_4 and R_5 are
 hydrogen.

30. A compound according to claim 29, wherein R_2 is fluorine.

31. A compound according to claim 30, wherein, R_6 is $C(O)CH_3$.

32. A compound according to claim 31, wherein R_1 is $C(O)NR_7R_8$ and

R₇ is hydrogen.

33. A compound according to claim 32, wherein R₈ is heteroaryl.
34. A biologically active oxazolidinone derived from a combinatorial library according to claim 17.
- 5 35. A compound according to claim 19, wherein R₃, R₄ and R₅ are hydrogen.
36. A compound according to claim 26, wherein R₃, R₄ and R₅ are hydrogen.
- 10 37. A compound according to claim 27, wherein R₃, R₄ and R₅ are hydrogen.
38. A compound according to claim 35, wherein R₂ is fluorine.
39. A compound according to claim 36, wherein R₂ is fluorine.
40. A compound according to claim 37, wherein R₂ is fluorine.
- 15 41. A compound according to claim 38, wherein R₆ is C(O)CH₃, and NR₇R₈ is NH(5'-(5-aminopyridine-2-yl)thiopyridine-3'-yl) or NH(pyridine-3-yl).
42. A compound according to claim 38, wherein R₆ is C(O)CH₂SMe, and NR₇R₈ is NH(5-chloropyridine-3-yl).
43. A compound according to claim 38, wherein R₆ is C(O)CHCH(pyridine-3-yl), and R₇R₈ is NH(5-chloropyridine-3-yl).
- 20 44. A method of preparing the combinatorial libraries according to claim 17, comprising the steps of:
- a) attaching a plurality of aryl oxazolidinones to a plurality of solid supports;
 - b) functionalizing the 4-position of the aryl groups of the attached oxazolidinones; and, optionally,
 - c) removing the oxazolidinones from the solid supports.
- 25 45. The method according to claim 44, wherein the aryl oxazolidinone is attached to a solid support through the reaction of an iminophosphorane with a carbonyl containing resin to form an imine.
- 30 46. The method according to claim 44, wherein the aryl oxazolidinone is attached to a solid support through the reaction of an amine with a carbonyl containing resin to form an imine.

47. The method according to claim 45, wherein the attachment further comprises the step of reducing the imine.

48. The method according to claim 46, wherein the attachment further comprises the step of reducing the imine.


49. A method of synthesizing the compounds according to claim 16, wherein the method comprises the steps of:

- a) providing an iminophosphorane;
- b) mixing the iminophosphorane with a resin that comprises carbonyl groups to form an imine intermediate; and,
- c) reducing the imine intermediate to afford a compound attached to the resin through an amine linkage.

50. A method according to claim 49, wherein the iminophosphorane is provided from an azide that is reacted with a phosphine.

51. A method according to claim 49, wherein the iminophosphorane is provided from an amine that is reacted with a (trisubstituted)phosphine dihalide.

52. A method according to claim 49, wherein the resin comprising carbonyl groups is of the structure



1c

wherein R_{23} is hydrogen, alkyl, aryl, O-alkyl or O-aryl; R_{24} is hydrogen, CH_3O or NO_2 ; R_{25} is $(\text{CH}_2)_n\text{CONH}$, wherein n is an integer between 1 and about 5; and, the filled circle is a polymeric support.


53. A method according to claim 52, wherein R_{23} is hydrogen, R_{24} is CH_3O , R_{25} is $(\text{CH}_2)_3\text{CONH}$, and the filled circle is Tentagel, (cross-linked)polystyrene, (cross-linked)polyethyleneglycol or polyethyleneglycol-polystyrene compositions.

54. A method of synthesizing a compound according to claim 16, wherein the method comprises the steps of:


- a) reacting an amine with a resin that comprises carbonyl groups to form an imine intermediate; and
- b) reducing the imine intermediate to afford a compound attached to the resin through an amine linkage.

5


55. The compound of claim 14 selected from the group consisting of




10




15




56. The compound of claim 14 selected from the group consisting of




20










57. The compound of claim 14 selected from the group consisting of





5




10



15




; and




5


58. The compound of claim 14 selected from the group consisting of



10




;




;


15




;




;




;







; and



59. The compound of claim 14 selected from the group consisting of



;



60. The compound of claim 14 wherein:

R_6 is $C(=O)R$, wherein R is H, alkyl, heteroalkyl, aryl or


heteroaryl;



R_7 is aryl;

R_8 is $NH(C=O)$; and


R_9 is hydrogen or OH.

61. The compound of claim 14 wherein the compound is selected from the group consisting of:





62. A compound of formula 3c



wherein:

R_2 , R_3 , R_4 and R_5 are, independently, hydrogen, alkyl, heteroalkyl, heteroaryl or an electron withdrawing group;

R_6 is acyl or sulfonyl;

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $NRC(=O)$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$, wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl; and

R_9 is alkyl, aryl, heteroalkyl, or heteroaryl.

63. The compound of claim 62, wherein




R_6 is $C(=O)CH_3$;

R_7 is aryl;



R_8 is S; and


R_9 is heteroalkyl.

64. The compound of claim 62, wherein the compound is selected from the group consisting of




65. The compound of claim 62, wherein the compound is selected from the group consisting of







; and




- 5 66. The compound of claim 62, wherein the compound is selected from the group consisting of



;



; and



15

67. The compound of claim 62 wherein:



R_6 is $C(=O)CH_3$;

R_7 is aryl;


R_8 is $OC(=O)$; and

R₉ is alkyl.

68. The compound of claim 62 selected from the group consisting of:



69. A compound of formula 4c:



wherein:

R₆ is acyl or sulfonyl;

Het₁ is heteroaryl;


R₈ is C₁-C₇ alkyl, NR, O, S, C(=O)NR, C(=O)NOR, NRC(=O), C(=O),

20 C(=O)O, OC(=O), S(=O), SO₂, SO₂NR, NRSO₂, NRCONR', or (CH₂)_nO,

wherein n = 0-6, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl; and

R₉ is alkyl, aryl, heteroalkyl, or heteroaryl.

70. A compound of formula 5c:



5c

5

wherein:

R_2 , R_3 , R_4 and R_5 are, independently, hydrogen, alkyl, heteroalkyl, heteroaryl or an electron withdrawing group;

R_6 is acyl or sulfonyl;

10

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $NRC(=O)$, $C(=O)NOR$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$, wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl; and

Het₂ is a heterocyclic group.

15

71. The compound of claim 70, wherein

R_6 is $C(=O)CH_3$;


R_7 is aryl;

R_8 is S; and


20

Het₂ is a thienylphenyl or thiazolyl group.

72. The compound of claim 70 selected from the group consisting of:



25



73. The compound of claim 70 wherein:




R₆ is C(=O)CH₃;

R₇ is aryl;


R₈ is NH; and

Het₂ is 1,3,5-triazinyl.

74. The compound of claim 70 selected from the group consisting of



75. A compound of formula 6c:



wherein:

5

R_6 is acyl or sulfonyl;

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $NRC(=O)$, $C(=O)NOR$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$, wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl;

10

Het₁ is heteroaryl; and

Het₂ is a heterocyclic group.

76. The compound of claim 75 wherein

15



Het₁ is selected from the group consisting of thienylphenyl, thiazolyl, 1,3,4-thiadiazolyl, pyridinyl, pyrimidinyl, phenyl and fluorophenyl; and

20

Het₂ is selected from the group consisting of oxazolyl, isoxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-oxadiazolyl, thienylphenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-triazinyl, 1,2,4-triazinyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, and 1,2,4,5-tetrazinyl.

25

77. A compound of formulas 7c or 8c:



wherein:


R_6 is acyl or sulfonyl;

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $C(=O)NOR$, $NRC(=O)$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$, wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl;


R_9 is alkyl, aryl, heteroalkyl, or heteroaryl; and

R_{10} , R_{11} and R_{12} are independently hydrogen, alkyl, aryl, heteroalkyl, electron withdrawing group, F, Cl, CN, NO_2 , $NR''R'''$, OR'' , SR'' , $S(=O)R''$, SO_2R'' , $C(=O)R''$, $C(=O)OR''$, $OC(=O)R''$, $C(=O)NR''R'''$, $N(R'')C(=O)R'''$, or N-oxide group in the pyridine nuclei, wherein R'' and R''' are independently H, alkyl, heteroalkyl, aryl or heteroaryl.

78. A compound of formula 9c or 10c:



9c



10c

5

wherein:


R₆ is acyl or sulfonyl;

10 R₈ is C₁-C₇ alkyl, NR, O, S, C(=O)NR, C(=O)NOR, NRC(=O), C(=O), C(=O)O, OC(=O), S(=O), SO₂, SO₂NR, NRSO₂, NRCONR', or (CH₂)_nO, where n = 0-6, and where R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl;



R₉ is alkyl, aryl, heteroalkyl, or heteroaryl; and

15 R₁₀ and R₁₁ are independently hydrogen, alkyl, aryl, heteroalkyl, electron withdrawing group, F, Cl, CN, NO₂, NR''R''', OR'', SR'', S(=O)R'', SO₂R'', C(=O)R'', C(=O)OR'', OC(=O)R'', C(=O)NR''R''', N(R'')C(=O)R''', or N-oxide group in the pyrimidine nuclei, wherein R' and R''' are independently H, alkyl, heteroalkyl, aryl or heteroaryl.

20 79. A compound of formula 11c, 12c or 13c:



11c



wherein:


R_6 is acyl or sulfonyl;



R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $C(=O)NOR$, $NRC(=O)$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$,
 wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl,
 aryl or heteroaryl;

R_9 is alkyl, aryl, heteroalkyl, or heteroaryl; and

R_{10} and R_{11} are independently hydrogen, alkyl, aryl, heteroalkyl, electron
 withdrawing group, F, Cl, CN, NO_2 , $NR''R'''$, OR'' , SR'' , $S(=O)R''$, SO_2R'' ,
 $C(=O)R''$, $C(=O)OR''$, $OC(=O)R''$, $C(=O)NR''R'''$, or $N(R'')C(=O)R'''$,
 wherein R'' and R''' are independently H, alkyl, heteroalkyl, aryl or heteroaryl.

80. A compound of formula 14c, 15c or 16c:





wherein:


R_6 is acyl or sulfonyl;

R_8 is C_1 - C_7 alkyl, NR, O, S, $C(=O)NR$, $C(=O)NOR$, $NRC(=O)$, $C(=O)$, $C(=O)O$, $OC(=O)$, $S(=O)$, SO_2 , SO_2NR , $NRSO_2$, $NRCONR'$, or $(CH_2)_nO$,
 wherein $n = 0-6$, and wherein R and R' are independently H, alkyl, heteroalkyl,
 aryl or heteroaryl;

R_9 is alkyl, aryl, heteroalkyl, or heteroaryl; and

R_{10} is hydrogen, alkyl, aryl, heteroalkyl, electron withdrawing group, F,
 Cl, CN, NO_2 , $NR''R'''$, OR'' , SR'' , $S(=O)R''$, SO_2R'' , $C(=O)R''$, $C(=O)OR''$,
 $OC(=O)R''$, $C(=O)NR''R'''$, or $N(R'')C(=O)R'''$, where R'' and R''' are
 independently H, alkyl, heteroalkyl, aryl or heteroaryl.

81. A compound of formula **17c**:



wherein:

R_6 is acyl or sulfonyl;


R₈ is C₁-C₇ alkyl, NR, O, S, C(=O)NR, C(=O)NOR, NRC(=O), C(=O), C(=O)O, OC(=O), S(=O), SO₂, SO₂NR, NRSO₂, NRCONR', or (CH₂)_nO, where n = 0-6, and where R and R' are independently H, alkyl, heteroalkyl, aryl or heteroaryl; and

5 R₉ is alkyl, aryl, heteroalkyl, or heteroaryl.

82. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 14 and a pharmaceutically acceptable carrier.


10

83. The composition of claim 82 wherein the compound is




15

84. The composition of claim 82 wherein the compound is




85. The composition of claim 82 wherein the compound is




20


86. The composition of claim 82 wherein the compound is



87. The composition of claim 82 wherein the compound is




88. The composition of claim 82 wherein the compound is



89. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 55 and a pharmaceutically acceptable carrier.

90. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 57 and a pharmaceutically acceptable carrier.

91. The composition of claim 82, wherein the compound is



92. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 61 and a pharmaceutically acceptable carrier.

93. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 64 and a pharmaceutically acceptable carrier.

5

94. A composition for the treatment or prevention of an infectious disorder comprising an effective amount of a compound of claim 72 and a pharmaceutically acceptable carrier.

10

95. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 14.

15

96. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 55.

20

97. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 57.

25

98. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 61.

30

99. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 64.

100. A method of treating or preventing an infectious disorder in a human or other animal subject, comprising administering to the subject an effective amount of a compound of claim 72.